Tofacitinib Prevents Radiographic Progression in Rheumatoid Arthritis
Journal of Korean Medical Science
;
: 1134-1138, 2013.
Artigo
em Inglês
| WPRIM
| ID: wpr-135448
ABSTRACT
Tofacitinib, a novel Janus kinase inhibitor, may prevent structural damage in rheumatoid arthritis (RA). In this cohort study, we compared radiographic progression of hand joints between 21 RA patients who took tofacitinb for 18 months in a phase IIb and its extension study and 42 patients who took conventional disease modifying antirheumatic drugs (DMARDs), using simple erosion narrowing score. For tofacitinib group, changes before and after the treatment were also compared. The changes of erosion and sum scores were significantly less in tofacitinib than DMARDs group (for erosion, -0.60 +/- 1.83 vs 0.51 +/- 1.77, P = 0.038; for sum, -0.50 +/- 1.72 vs 1.57 +/- 4.13, P = 0.012). Joint space narrowing score (JSN) was also less in tofacitinib group (0.095 +/- 0.58 vs 1.06 +/- 2.60, P = 0.055). In tofacitinib group, yearly rates of both erosion and JSN were significantly decreased after administration of tofacitinib (For erosion, 0.62 +/- 0.93 to -0.14 +/- 0.48, P = 0.009; for JSN, 0.47 +/- 0.64 to 0.03 +/- 0.40, P = 0.032), as was change of sum score (1.09 +/- 1.27 to -0.10 +/- 0.63, P < 0.001). In conclusion, tofacitinib may prevent structural damage caused by RA.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Piperidinas
/
Artrite Reumatoide
/
Pirimidinas
/
Pirróis
/
Índice de Gravidade de Doença
/
Estudos de Coortes
/
Resultado do Tratamento
/
Progressão da Doença
/
Antirreumáticos
/
Inibidores de Proteínas Quinases
Tipo de estudo:
Estudo de etiologia
/
Estudo de incidência
/
Estudo observacional
/
Fatores de risco
Limite:
Adulto
/
Idoso
/
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Journal of Korean Medical Science
Ano de publicação:
2013
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS